<DOC>
	<DOCNO>NCT00354406</DOCNO>
	<brief_summary>Abciximab demonstrate improve outcome administer primary angioplasty patient acute myocardial infarction . The Primary Objective study demonstrate early ( transportation form remote hospital cath lab ) abciximab administration acute myocardial infarction reduces infarct size compare late ( prior PCI ) abciximab administration , measure delayed enhancement magnetic resonance ( MR ) 6 month .</brief_summary>
	<brief_title>Efficacy Study Early Versus Late Abciximab Administration During Primary Coronary Angioplasty</brief_title>
	<detailed_description>Strategies direct improve myocardial perfusion viability set acute myocardial infarction ( AMI ) currently suboptimal . The consequence microvascular damage , assess TIMI myocardial perfusion ( TMP ) grade cardiac magnetic resonance imaging ( MR ) , serious affect survival AMI . Because size infarct important predictor prognosis , precise determination infarct size allow risk stratification patient AMI . First-pass MR perfusion study recently develop provide quantification absolute measure myocardial blood flow well direct visualization myocardial perfusion abnormality , area `` no-reflow '' . The hyperenhancement technique ( Delayed enhancement ) identify viable nonviable myocardium well no-reflow area . A recent pilot study show infarct size measure scintigraphy 7 day 23 % vs 14 % abciximab administer cath lab v emergency room , reduction infarct size 40 % . The present study conduct Cardiothoracic Department University Pisa together Institute Clinical Physiology ( CNR ) two Cath Labs West Tuscany . Each Cath Lab treat patient enrol peripheral hospital refer patient primary PCI . The primary objective study demonstrate early abciximab administration ( transfer ) compare late abciximab administration ( Cath Lab ) reduce infarct size measure delayed hyperenhancement image 6 month . The major secondary objective substudy demonstrate early abciximab administration : 1 . Improves angiographic TMP grade cTFC compare primary PCI group , immediately PCI . 2 . Reduces extension no-reflow area , assess DE-MRI discharge . 3 . Reduces extension microvasculature damage assess fist-pass perfusion study MRI discharge . 4 . Improves regional wall motion leave ventricular ejection fraction ( LVEF ) measure cine MR 2D echocardiography 6 month 5 . Reduces occurrence LV remodel 6 month follow .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Abciximab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Immunoglobulin Fab Fragments</mesh_term>
	<criteria>Prolonged , continuous sign symptom ischemia last 20 min , start within 6 hour prior randomization , ST segment elevation ≥ 2mm new leave bundle branch block Absence contraindication Abciximab ( detail cf . section ) Written informed consent Lowrisk ( ST elevation ≤2 lead ) inferior AMI Previous infarction area ( assessed ECG ) PCI 2 week prior AMI Know hypersensitivity abciximab Active internal bleeding History cerebrovascular accident previous 2 year cerebrovascular accident significant residual neurological deficit Head spine surgery trauma previous 2 month Recent ( within six week ) gastrointestinal ( GI ) genitourinary ( GU ) bleed clinical significance Administration oral anticoagulant within seven day unless prothrombin time &lt; 1.2 time control Bleeding diathesis severe uncontrolled arterial hypertension Thrombocytopenia ( &lt; 100 000 cells/mL ) Recent ( within six week ) major surgery trauma Intracranial neoplasm , arteriovenous malformation , aneurysm Severe renal liver failure Allergy aspirin Contraindication MRI examination</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Abciximab</keyword>
	<keyword>Magnetic Resonance Imaging</keyword>
	<keyword>Percutaneous Transluminal Coronary Angioplasty</keyword>
</DOC>